Affordable Access

Publisher Website

Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication

Authors
Journal
Journal of Clinical Biochemistry and Nutrition
0912-0009
Publisher
The Society for Free Radical Research Japan
Publication Date
Volume
44
Issue
2
Identifiers
DOI: 10.3164/jcbn.08-220r
Keywords
  • Review Article
Disciplines
  • Medicine

Abstract

Currently, a standard third-line therapy for Helicobacter pylori (H. pylori) eradication remains to be established. Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori. Several authors have studied quinolone-based third-line therapy and reported encouraging results, with the reported H. pylori cure rates ranging from 60% to 84%. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs. We recently reported a significant difference in the eradication rate obtained between patients infected with gatifloxacin-susceptible and gatifloxacin-resistant H. pylori, suggesting that the selection of quinolones for third-line therapy should be based on the results of drug susceptibility testing. As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Quinolone-Based Third-Line Therapy for Helicobacte...

on Journal of clinical biochemist... March 2009

Quinolone-Based Third-Line Therapy for Helicobacte...

on Journal of Clinical Biochemist... Feb 28, 2009

A third-line levofloxacin-based rescue therapy for...

on Digestive and Liver Disease April 2003

Dual therapy for third-line Helicobacter pylori er...

on World Journal of Gastroenterol... Jun 07, 2012
More articles like this..